Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965 | Completed Phase 1

• 1 other identifier: SCY-635-104
• Study Type: interventional
• Target: 57
• Locations: 1 country
• Sites: 2

Brief Summary

This study will examine the effectiveness of 15 days of therapy with SCY-635 in reducing hepatitis C virus (HCV) RNA levels.

Conditions

Chronic Hepatitis C

Outcome Measures

Primary Outcomes (2)

• Plasma HCV RNA level

  22 days

• Incidence and severity of treatment-emergent adverse events and changes in laboratory values as measures of safety and tolerability.

  22 days

Secondary Outcomes (1)

• Pharmacokinetic assessment of SCY-635

  22 days

Study Arms (7)

Placebo comparator

PLACEBO COMPARATOR

Drug: Placebo

SCY-635 30 mg once daily

ACTIVE COMPARATOR

Drug: SCY-635

SCY-635 100 mg once daily

ACTIVE COMPARATOR

Drug: SCY-635

SCY-635 300 mg once daily

ACTIVE COMPARATOR

Drug: SCY-635

SCY-635 100 mg three times daily

ACTIVE COMPARATOR

Drug: SCY-635

SCY-635 200 mg three times daily

ACTIVE COMPARATOR

Drug: SCY-635

SCY-635 300 mg three times daily

ACTIVE COMPARATOR

Drug: SCY-635

Interventions

Placebo DRUG

Oral tablet given once or three times daily for 15 consecutive days

Placebo comparator

SCY-635 DRUG

oral capsule

SCY-635 100 mg once daily; SCY-635 100 mg three times daily; SCY-635 200 mg three times daily; SCY-635 30 mg once daily; SCY-635 300 mg once daily; SCY-635 300 mg three times daily

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject is either male or female, between the ages of 18 and 65 years (inclusive).
• The subject has read and signed a Subject Informed Consent form to participate in the study. If the subject is not fluent in English, the Subject Informed Consent form must be translated into his or her native language.
• Female subjects of childbearing potential (i.e., women not surgically sterile or at least two years postmenopausal) must agree to utilize one of the following forms of contraception from Screening through completion of the study: abstinence, barrier (condom, diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (six months minimum). Hormonal contraception (oral, transdermal, implant, or injection) is not permitted during the study period (i.e., from Screening through the Follow-up visit). Note: For women aged \<50 years, postmenopausal is defined as at least two years cessation of menses. For women aged ≥50 years, postmenopausal is defined as at least one year cessation of menses. Estrogen replacement is allowed during the study.
• The subject exhibits quantifiable plasma levels of HCV-specific RNA in excess of 100,000 IU/mL as determined by the quantitative Roche COBAS taqMan assay.
• The subject has a negative urine screen for amphetamines, barbiturates, cocaine, opiates, and phencyclidine at Screening.
• If female, the subject has a negative serum pregnancy test at Screening (within 30 days prior to dosing) and a negative urine pregnancy test on Study Day -1.

You may not qualify if:

• The subject has a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Principal Investigator, may jeopardize the safety of the subject or may impact the validity of the study results.
• The subject is infected with any HCV genotype other than genotype 1.
• The subject has documented positive antibody tests for Human Immunodeficiency Virus Types 1 or 2 (p24 antibody specific for HIV-1 or HIV-2) or Hepatitis B virus (HBV) surface antigen (HbSAg) or at Screening exhibits serologic evidence of infection with either HIV-1, HIV-2 or HBV.
• The subject has donated blood within 30 days prior to dosing or donated plasma within 14 days prior to dosing.
• The subject has used any investigational agent within three months prior to dosing.
• The subject has received any FDA-approved anti-HCV therapy (including ribavirin or any product that contains interferon) within three months prior to dosing.
• The subject exhibits evidence of decompensated liver disease, as marked by bilirubin greater than 4 mg/dL, albumin less than 3.0 g/dL, prothrombin time greater than 2 seconds prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy.
• The subject is an organ transplant recipient.
• The subject exhibits ALT values greater than or equal to 2.5 times the upper limit of normal.
• The subject exhibits evidence of hepatocellular carcinoma either by exhibiting a serum alpha-fetoprotein concentration which exceeds 50 mg/L or by exhibiting a mass suggestive of liver cancer by ultrasound or other imaging technology.
• The subject exhibits evidence of ongoing alcohol or substance abuse.

Sponsors & Collaborators

• Scynexis, Inc.: lead

Study Sites (2)

Quest Clinical Research

San Francisco, California, 94115, United States

Location

McGuire Veterans Affairs Medical Center

Richmond, Virginia, 23249, United States

Location

Related Publications (1)

• Hopkins S, DiMassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scorneaux B, Mosier S, Kowalczyk P, Ribeill Y, Baugh J, Gallay P. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol. 2012 Jul;57(1):47-54. doi: 10.1016/j.jhep.2012.02.024. Epub 2012 Mar 13.

  PMID: 22425702 DERIVED

MeSH Terms

Conditions

Hepatitis C, Chronic

Interventions

SCY-635

Condition Hierarchy (Ancestors)

Hepatitis C; Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis, Chronic; Hepatitis; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Douglas Heuman, MD

  McGuire Veterans Affairs Medical Center, Richmond, Virginia

  PRINCIPAL INVESTIGATOR

• Jacob Lalezari, MD

  Quest Clinical Research, San Francisco, California

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 4, 2011
• First Posted: February 7, 2011
• Study Start: April 1, 2007
• Primary Completion: December 1, 2008
• Study Completion: January 1, 2009
• Last Updated: November 6, 2014

Record last verified: 2011-02

Locations

US (2)